AUS
NZ
UK
CA
USA
IND
Highlights:
Anteris Technologies progresses with pivotal PARADIGM Trial for DurAVR® transcatheter heart valve system.
Focus on technical, clinical, and regulatory efforts to support FDA submission.
Company expands its clinical team and manufacturing facilities to meet global trial demands.
Anteris Technologies Global Corp is an Australian-based structural heart valve company actively developing its DurAVR® transcatheter heart valve (THV) system. As the company prepares for its pivotal PARADIGM Trial, Anteris remains a notable player in the ASX 200, reflecting its increasing prominence in the global medical device industry.
Scaling Up for the PARADIGM Trial
Anteris Technologies has entered a critical phase in its research and development cycle, ramping up its efforts for the global PARADIGM Trial. This trial is designed to assess the DurAVR® system against current leading transcatheter aortic valve replacement (TAVR) devices. The company has significantly increased its investment in clinical activities, including regulatory and technical work, to prepare for the trial's initiation.
A major milestone was reached during the reporting period with the successful submission of an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA). This application marks a crucial step in advancing the PARADIGM Trial, which is expected to provide valuable clinical data regarding the effectiveness and safety of the DurAVR® device.
Progress in Clinical Milestones
Anteris surpassed a key clinical milestone, treating over 100 patients with the DurAVR® device. This includes patients suffering from de novo aortic stenosis as well as those undergoing valve-in-valve procedures. Of the 100 patients, a significant portion completed the primary safety and efficacy endpoint within the first 30 days, yielding promising clinical results.
The ongoing clinical program has been noted for its significant differentiation from existing valve replacement therapies. Data shared at a leading structural heart conference highlighted the DurAVR® system’s strong safety profile, with no reported cases of prosthesis-patient mismatch—a complication often seen in existing devices. These results further affirm the potential advantages of the DurAVR® system in addressing key challenges within the field of heart valve treatments.
Expansion in Clinical and Manufacturing Capabilities
In line with its growing clinical program, Anteris has significantly expanded its global clinical specialist team, securing contracts with medical centers across the U.S., Canada, and Europe. This expansion ensures that the company is well-positioned to meet the demands of the upcoming trial, with a diverse and experienced team supporting its operations.
Additionally, Anteris has scaled its manufacturing capabilities, establishing new ISO-qualified clean room facilities and increasing its production capacity. These investments aim to triple the company's output, ensuring it can meet the demands of the PARADIGM Trial while maintaining high-quality standards across its supply chain, which now spans both the U.S. and Australia.
Financial Overview and R&D Investments
Anteris reported a significant increase in its research and development spending, with a marked rise in costs due to the scale-up of its clinical trial preparations and technical advancements. The company is focusing its financial resources on ensuring the success of the PARADIGM Trial and advancing the DurAVR® technology.
In contrast, the company saw a decline in its revenue during the period, attributed to softer demand for its tissue products. Despite this, Anteris ended the quarter with a strong cash position, bolstered by its recent addition to the FTSE Russell 2000® Index, which reflects its growing influence in the U.S. small-cap equity market.
Future Outlook
The company anticipates that the PARADIGM Trial will commence in the third quarter of 2025, pending the FDA’s approval of its IDE application. As Anteris continues to scale its operations, the success of the trial will be pivotal in determining the future trajectory of its DurAVR® system in the competitive TAVR market.
This focused investment in the clinical and regulatory aspects of its business, along with ongoing infrastructure expansion, positions Anteris Technologies for continued progress within the structural heart valve space, contributing to its role as a key player in the ASX 200.
